Clinical Trials Logo

Metastatic Pancreatic Cancer clinical trials

View clinical trials related to Metastatic Pancreatic Cancer.

Filter by:

NCT ID: NCT01510561 Withdrawn - Pancreatic Cancer Clinical Trials

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Start date: March 2012
Phase: Phase 1
Study type: Interventional

90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are then followed weekly for 12 weeks and afterwards for up to 1 year.